primary cutaneous diffuse large B-cell lymphoma, Leg type
disease diseaseOn this page
Also known as PCDLBCL,LT
Summary
primary cutaneous diffuse large B-cell lymphoma, Leg type (MONDO:0006383) is a cancer and 6 clinical trials. Top therapeutic interventions include azacitidine, cyclophosphamide anhydrous, and tafasitamab. A subtype of diffuse large B-cell lymphoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 6
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | primary cutaneous diffuse large B-cell lymphoma, Leg type |
| Mondo ID | MONDO:0006383 |
| EFO | EFO:1000490 |
| Orphanet | 178544 |
| ICD-11 | 1418101362 |
| NCIT | C45194 |
| UMLS | C1709656 |
| MedGen | 311155 |
| GARD | 0020160 |
| Is cancer (heuristic) | yes |
Also known as: PCDLBCL,LT · primary cutaneous diffuse large B-cell lymphoma, Leg type
Data availability: 1 cell line.
Disease family
This is a subtype of diffuse large B-cell lymphoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › immune system disorder › leukocyte disorder › B-cell neoplasm › neoplasm of mature B-cells › diffuse large B-cell lymphoma › primary cutaneous diffuse large B-cell lymphoma, Leg type
Related subtypes (29): relapsed/refractory diffuse large B-cell lymphoma, breast diffuse large B-cell lymphoma, colorectal diffuse large B-cell lymphoma, gastric diffuse large B-cell lymphoma, liver diffuse large B-cell lymphoma, primary pulmonary diffuse large B-cell lymphoma, small intestinal diffuse large B-cell lymphoma, splenic diffuse large B-cell lymphoma, thyroid gland diffuse large B-cell lymphoma, Epstein-Barr virus-positive diffuse large B-cell lymphoma of the elderly, plasmablastic lymphoma, diffuse large B-cell lymphoma of the central nervous system, T-cell/histiocyte rich large B cell lymphoma, diffuse large B-cell lymphoma with chronic inflammation, ALK-positive large B-cell lymphoma, primary effusion lymphoma, lymphomatoid granulomatosis, primary mediastinal large B-cell lymphoma, intravascular large B-cell lymphoma, high grade B-cell lymphoma, diffuse large B-cell lymphoma activated B-cell type, diffuse large B-cell lymphoma germinal center B-cell type, BN2 diffuse large B-cell lymphoma, EZB diffuse large B-cell lymphoma, MCD diffuse large B-cell lymphoma, N1 diffuse large B-cell lymphoma, ST2 diffuse large B-cell lymphoma, A53 diffuse large B-cell lymphoma, primary vitreoretinal large b-cell lymphoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 6.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE2 | 5 |
| PHASE2/PHASE3 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT04799275 | PHASE2/PHASE3 | ACTIVE_NOT_RECRUITING | Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma |
| NCT03038672 | PHASE2 | ACTIVE_NOT_RECRUITING | Nivolumab With or Without Varlilumab in Treating Patients With Relapsed or Refractory Aggressive B-cell Lymphomas |
| NCT05202782 | PHASE2 | ACTIVE_NOT_RECRUITING | Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin’s Lymphoma or Transformed Indolent B-cell Lymphoma |
| NCT05507541 | PHASE2 | ACTIVE_NOT_RECRUITING | TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma |
| NCT05821088 | PHASE2 | RECRUITING | Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma |
| NCT06834373 | PHASE2 | RECRUITING | Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| AZACITIDINE | 4 | 1 |
| CYCLOPHOSPHAMIDE ANHYDROUS | 4 | 1 |
| TAFASITAMAB | 4 | 1 |
| ZANUBRUTINIB | 4 | 1 |
| GOLCADOMIDE | 3 | 1 |
| MAPLIRPACEPT | 2 | 1 |
| ONTORPACEPT | 2 | 1 |
| VARLILUMAB | 2 | 1 |
| CHEMBL5193128 | 0 | 1 |